Tcr Inhibitory Molecule As A Promising Allogeneic Nkg2d Car-T Cell Approach

e15042Background: Most CAR T cell therapy relies on autologous cells with potential limitation in quality of the cells. Cells derived from an allogeneic healthy donor may be more consistent in quality but their use raises two issues: the elimination of the donor T cells due to the host versus graft (HvG) response, and graft versus host disease (GvHD) due to the recognition of non-self molecules expressed on recipient cells by the T Cell Receptor (TCR) of donor cells therefore leading to potential safety concerns for the recipient. HvG can be controlled by pre-conditioning of the patient. However, to avoid GvHD, TCR signalling of the donor T cells could be inhibited by means of the expression of a truncated form of CD3z called TIM (TCR inhibitory molecule). Theobjective of that study was to assess TIM functionality in human primary T cells in combination with an NKG2D-based CAR Methods: Peripheral blood mononuclear cells from healthy donors were transduced with the appropriate vectors with subsequent enric...